Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case

Thursday, March 22, 2007 1:59 pm EDT

Dateline:

NEW YORK

Public Company Information:

NYSE:
PFE
US7170811035

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the companys U.S. patent covering amlodipine besylate, the active ingredient in Norvasc.

Pfizer is reviewing the decision and is considering all its options, including seeking reconsideration.

Generic manufacturer Apotex filed the appeal after a lower court in the Northern District of Illinois had ruled that the Pfizer patent was valid and enforceable. The appellate panel ruled that the patent (U.S. Patent No. 4,879,303) covering amlodipine besylate is invalid.

Pfizer disagrees with this decision. The company noted that two other trial courts had also found this patent to be valid and infringed.

Contact:

Pfizer Inc
Bryant Haskins, 212-733-8719